Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
MYH10 CRISPR/Cas9 KO Plasmid (h): sc-401835
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MYH10 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the MYH10 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MYH10 Antibody (A-3): sc-376942
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MYH10 CRISPR/Cas9 KO Plasmid (h) | sc-401835 | 20 µg | $397.00 |
Overview
MYH10 encodes non-muscle myosin IIB, an actin-based motor protein that generates contractile force and supports cytoskeletal remodeling in human cells. It participates in actomyosin network organization, cell migration, adhesion, cytokinesis, and maintenance of cell polarity through regulation of stress fibers and contractile ring dynamics. MYH10 function intersects with pathways controlling morphogenesis and mechanotransduction, linking motor activity to changes in cell shape and tissue architecture. Altered MYH10 expression or activity has been associated with defects in development and cell division and is frequently studied in the context of dysregulated cytoskeletal dynamics in cancer and neurodevelopmental disease models.
MYH10 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the MYH10 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the MYH10 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the MYH10 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish MYH10 protein expression.
This CRISPR knockout system enables efficient generation of MYH10-deficient cell models for investigation of MYH10 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting MYH10 exon(s) critical for MYH10 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple MYH10 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by MYH10 CRISPR/Cas9 KO Plasmid (h) and MYH10 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the MYH10 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by MYH10 HDR Plasmid (h) and MYH10 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by MYH10 homology arms to support homology-directed repair at defined MYH10 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.